Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TQC2938 injection with background therapy in seasonal allergic rhinitis
CTR20252117Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQC2938 in seasonal allergic rhinitis (SAR), sponsored by Nanjing Shunxin Pharmaceutical. Started May 2025; status: completed.
02
Drugs
TQC2938
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20252117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252117.